IndustryCompany release

Metagenomi puts hemophilia A editing candidate MGX-001 first in November 2026 deck

🇺🇸 Metagenomi Therapeutics, Inc. (MGX) · Mon 16 Nov 2026

The in vivo CRISPR company reports $101.7 million in cash at the end of Q3 2026, which it expects to fund operations into 2028.

Metagenomi Therapeutics has issued a corporate presentation for November 2026 that sets out its in vivo CRISPR gene-editing pipeline, with hemophilia A candidate MGX-001 as the lead programme.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Metagenomi Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Metagenomi Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →